Clinical Trial

A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Name: A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104) — clinical trial record (NCT07547787)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.

Trial Details

NCT Number	NCT07547787
Lead Sponsor	Akeso
Conditions	Locally Advanced Unresectable or Metastatic Gastric Cancer
Enrollment	610 participants
Start Date	2024-12-26
Primary Completion	2030-12-31 (estimated)
Study Completion	2040-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-23